Jefferson Brain Tumor Center

Our Mission

The Division of Neuro-Oncology was established within the Department in 1995 by David W. Andrews, MD, Professor of Neurological Surgery. The Division was established to provide multimodality and interdisciplinary care for patients with brain tumors while simultaneously advancing our knowledge and treatment of brain tumors.

Our Team

At the Jefferson Brain Tumor Center we have experts in all aspects of benign and malignant brain tumor care and work closely with our colleagues in Radiation Oncology, Neurology, Oncology, Otolaryngology and Radiology.

Services

Encompassing benign extra-axial tumor and Intra-axial low grade and malignant tumors our specialists have developed advanced techniques for treating the most complex of tumors in any location in the central nervous system.

Faculty

David Andrews, MD

Professor, Neurological Surgery

James Evans, MD

Professor, Neurological Surgery & Otolaryngology
Division Chief, Brain Tumor and Stereotactic Radiosurgery Division
Director, Cranial Base and Pituitary Surgery
Director, Cranial Base and Endoscopic Surgery Fellowship

Christopher Farrell, MD

Assistant Professor, Neurological Surgery

Jon Glass, MD

Professor, Neurology

Kevin Judy, MD

Professor, Neurological Surgery

Our team of Neuro-Oncologists coordinate comprehensive and cutting edge treatment for our patients. We systematically review each case at our weekly multidisciplinary Brain Tumor Board and actively engage our patients in a number of ongoing institutional and national clinical trials.

Faculty

Jon Glass, MD

Professor, Neurology

At the Jefferson Hospital for Neuroscience, innovations in stereotactic radiosurgery have been ongoing since the inception of the program in 1994. With a Gamma Knife and the world’s first installation of a linear accelerator designed for and dedicated to stereotactic radiation, neurosurgeons, radiation oncologists, and medical physicists have worked together to refine techniques in stereotactic radiation. They have pioneered fractionated stereotactic radiotherapy, or FSR for short, and designed national trials which have led to new standards of care for a variety of diseases including brain metastases, malignant gliomas, acoustic neuromas, and optic nerve sheath meningiomas. For these diseases, FSR has prolonged life, preserved hearing, and recovered vision in patients who otherwise would have had no options.

Publications which have reshaped standard practice include:

  • Neurosurgery 2002, the first paper describing FSR for optic nerve sheath meningiomas demonstrating recovery of vision (over 120 citations)
  • The International Journal of Radiation Oncology Biology and Physics 2001, the first paper demonstrating an advantage of FSR over single fraction radiosurgery for patients with acoustic neuromas (over 180 citations)
  • The Lancet 2004, the first prospective randomized trial demonstrating the benefit of radiosurgery when coupled to whole brain radiation for patients with brain metastases (over 890 citations)
  • The Journal of Clinical Oncology 2010, the first paper to demonstrate that FSR boost to recurrent gliomas is not only safe but effective in extending life with quality in patients with malignant gliomas (over 50 citations and serving as the basis for a new RTOG protocol)

As we look to the future, we are designing new protocols that promise to improve hearing in acoustic tumor patients and preserve cognition in patients with brain metastases. Our original linear acceleratorhas recently been replaced by the state-of-the-art Varian Truebeam STX Slim allowing us to achieve new heights in precisely sculpted patient-specific stereotactic radiation treatments.

Faculty

David Andrews, MD

Professor, Neurological Surgery

James Evans, MD

Professor, Neurological Surgery & Otolaryngology
Division Chief, Brain Tumor and Stereotactic Radiosurgery Division
Director, Cranial Base and Pituitary Surgery
Director, Cranial Base and Endoscopic Surgery Fellowship

Christopher Farrell, MD

Assistant Professor, Neurological Surgery

Jon Glass, MD

Professor, Neurology

Kevin Judy, MD

Professor, Neurological Surgery

Encompassing a wide variety of pathologies involving the skull base, our team of surgeons treat benign and malignant skull base tumors and perform decompression procedures for facial pain and hemi-facial spasm.

A multidisciplinary team of surgeons using minimally invasive endoscopic techniques to treat a variety of skull base tumors and conditions together with our colleagues from the Department of Otolaryngology - Head and Neck Surgery.

Clinical Trials & Research

At the Jefferson Brain Tumor Center we offer numerous cutting edge clinical trials for our patients and are involved in ongoing brain tumor research.

Neuro-Oncology & Skull Base Surgery Fellowship

We offer CAST- approved fellowship training in Surgical Neuro-Oncology and in Skull Base Surgery. Applications are accepted on an ongoing basis.

Brain Tumor Support Group

The group is open to patients with all types of brain tumors, along with their families. It offers a wonderful opportunity to meet others facing similar situations and feelings.